Showing posts with label death. Show all posts
Showing posts with label death. Show all posts

Saturday, September 22, 2012

Safety Alert!! issued by The FDA - Drug Product for Infectious Diarrhea



FDA ISSUES SAFETY ALERT ON INTESTINOMICINA, DRUG PRODUCT MARKETED AS TREATMENT FOR INFECTIOUS DIARRHEA



WOW This stuff is just death in a bottle. The article doesn't state if the product is an OTC or prescription drug.  I would say that with the chemicals included in this cocktail of toxic shit, that it would be something the doctor must order.  IDK.  For instance, Im allergic to sulfa med and break out into a rash that's so nasty.  pennicillin and all those antibiotics with "cillin" make me rash up too.  I have no clue what Neomycin would do.
I however, have never seen this drug on any drug store shelves.  As they said it is mostly sold in international grocery stores across the US, maybe this is why.  Really, no one knows what stores this stuff may have been sold in.  Just BEWARE of the stuff in the yellow box.




September 22, 2012 (Washington, D.C.) -- The U.S. Food and Drug Administration is warning consumers not to use Intestinomicina, a drug product manufactured in El Salvador and marketed as a treatment for infectious diarrhea and acute gastrointestinal infections. Consumers who have purchased this product should immediately stop taking it and consult with a health care provider.
Intestinominica contains the prescription drug ingredient, chloramphenicol. Oral forms of chloramphenicol were formally withdrawn from the United States market in July 2012 due to the risk of serious and life threatening injuries.
Intestinomicina is labeled primarily in Spanish and lists the ingredient as “chloramfenicol palmitato,” or chloramphenicol in English, on the label. It can be found in tablet and liquid forms and is manufactured by Laboratorios Lopez. The product has been found in international grocery stores in the United States that feature South and Central American specialty foods and products.
The most serious and life-threatening injury associated with oral chloramphenicol treatment is bone marrow toxicity, which occurs when the body does not produce enough red blood cells, white blood cells, and/or platelets. Certain types of bone marrow toxicity are reversible; however, in rare circumstances it can lead to death. Patients with anemia, low white or red blood cell count, or decreased blood platelets may be at a greater risk of death or serious injury.
The product label also lists antibacterial ingredients including neomycin, an antibiotic often found in topical medications, and sulfonamides, sometimes called sulfa drugs. Neomycin and sulfa drugs have the potential to cause a variety of adverse reactions, ranging from rashes and hives, to severe and life-threatening reactions.
Intestinomicina may also interact with other medications consumers may be taking.
Health care professionals and consumers are encouraged to report any adverse events related to Intestinomicina to FDA’s MedWatch Safety Information and Adverse Event Reporting Program:
  • online at http://www.fda.gov/Medwatch/report.htm;
  • by phone at 800-FDA-1088 (800-332-1088); or,
  • by returning FDA form 3500, available on the MedWatch “Download Forms” page by mail to the address on the pre-addressed form or by fax at 800-FDA-0178. 

Link:  FDA ISSUES SAFETY ALERT ON INTESTINOMICINA, DRUG PRODUCT MARKETED AS TREATMENT FOR INFECTIOUS DIARRHEA | East County Magazine:

'via Blog this'


Thursday, April 21, 2011

Interesting article - IBD patients and the dangers of C diff


I thought this article was worth reading.  This info was found by London researchers.   

Bug linked to bowel disease deaths
A common hospital bug increases the risk of death for patients with inflammatory bowel disease (IBD) six-fold, research has shown.
Scientists called for all IBD patients to be screened on admission to hospital to protect them against Clostridium difficile (C diff).
IBD, which includes Crohn's disease and ulcerative colitis, affects about 240,000 people in the UK.
The autoimmune conditions cause symptoms of abdominal pain and diarrhoea, which can be severe enough to warrant admission to hospital.
Researchers in London looked at NHS admission records from 2002 to 2008 and found a strong link between IBD, C diff, and death in hospital.
IBD patients infected with C diff were six times more likely to die than those who escaped the bug. After 30 days, their mortality rate was as high as 25%.
The findings, reported in the journal Alimentary Pharmacology and Therapeutics, also showed that IBD patients with C diff had longer stays in hospital and were almost twice as likely to need gastrointestinal surgery.
Typically, they remained in hospital for 26 days, compared with five days for patients without C diff.
Dr Sonia Saxena, one of the researchers from the School of Public Health at Imperial College London, said: "Hospitals must do everything they can to control infections such as C difficile. We are asking for these high-risk patients to be screened for C difficile proactively on admission to hospital so that if they are exposed, they can be diagnosed and treated more quickly."
Co-author Dr Richard Pollok, from St George's Healthcare NHS Trust, said: "At St George's Hospital, we have seen a 70% reduction in hospital-acquired infections after implementing a range of control measures, such as careful handwashing and reduced use of broad spectrum antibiotics. But we need to do more to protect vulnerable patients such as those with IBD."